Ganglioside gm1,ammonium salt,bovine

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 鞘脂
• 英文名称: Ganglioside gm1,ammonium salt,bovine
• 英文别名: (2S,4S,5R,6R)-5-acetamido-2-[(2S,3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-6-[(E,2R,3S)-3-hydroxy-2-(icosanoylamino)icos-4-enoxy]-2-(hydroxymethyl)oxan-3-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
• 化学式: C₇₇H₁₃₉N₃O₃₁
• 分子量: 1602.9
• InChiKey: GTTLZSUWCRJZRC-CRQBLQEMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  111
• 可旋转键数：
  56
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  541
• 氢给体数：
  20
• 氢受体数：
  31

反应信息

• 作为反应物：
  描述：

  、 Ganglioside gm1,ammonium salt,bovine 、 disodium;carbonate 以produces the ganglioside GM1的产率得到ganglioside G_M1
  参考文献：
  名称：

  Ganglioside derivatives

  摘要：

  新的功能性神经节苷脂衍生物包括神经节苷脂的酯、酰胺和过酰化衍生物，其制备方法，含有其的制药制剂以及衍生物的治疗用途。

  公开号：

  US04849413A1

文献信息

• Retargeting of viruses or VLPs
  申请人：Deutsches Primatenzentrum GmbH Leibniz-Institut für Primatenforschung

  公开号：US10975359B2

  公开（公告）日：2021-04-13

  The present invention relates to a method of producing a polyomavirus or polyomavirus-derived virus-like particle (vlp) carrying on its surface at least one targeting molecule that binds to a cell of interest. Furthermore, the present invention relates to a composition comprising such a polyomavirus or polyomavirus-derived vlp and to the use of the polyomavirus or polyomavirus-derived vlp of the invention or the composition of the invention for use as a medicament. The present invention further relates to a kit comprising the polyomavirus or polyomavirus-derived vlp or the composition of the invention.

  本发明涉及一种生产多瘤病毒或多瘤病毒衍生病毒样颗粒（vlp）的方法，该病毒样颗粒表面携带至少一种与相关细胞结合的靶向分子。此外，本发明还涉及一种包含这种多瘤病毒或多瘤病毒衍生的病毒样颗粒的组合物，以及本发明的多瘤病毒或多瘤病毒衍生的病毒样颗粒或本发明的组合物作为药物的用途。本发明还涉及一种包含多瘤病毒或多瘤病毒衍生 vlp 或本发明组合物的试剂盒。
• AGENT DELIVERY SYSTEM
  申请人：WRS Nutraceuticals Pty Ltd

  公开号：US20190142761A1

  公开（公告）日：2019-05-16

  The invention provides an agent delivery system comprising an agent preparation encapsulated within a membrane composition. The invention further provides a membrane composition comprising a ganglioside and lipid for encapsulating agents, and processes for preparing the membrane compositions. The invention further provides agent preparations encapsulated within the membrane compositions, including a plurality of individual particles wherein each particle contains agent preparation individually encapsulated within membrane composition. The invention also provides processes for preparing encapsulated agent preparations or individual particles of encapsulated agent preparations. The agents may be biologically active including hydrophilic, hydrophobic, small molecule or large molecule therapeutic agents. The invention further provides pharmaceutical compositions comprising encapsulated agent preparations or individual particles of encapsulated agent preparations. The invention further provides methods for delivery of the encapsulated agent preparations or individual particles of encapsulated agent preparations to a subject, including oral delivery of large molecule therapeutic agents to the lymphatic system, blood circulatory system, and/or targeted delivery to cells, tissues or organs.
• RETARGETING OF VIRUSES OR VLPs
  申请人：DEUTSCHES PRIMATENZENTRUM GMBH (DPZ) - LEIBNIZ-INSTITUT FÜR PRIMATENFORSCHUNG

  公开号：US20190352617A1

  公开（公告）日：2019-11-21

  The present invention relates to a method of producing a polyomavirus or polyomavirus-derived virus-like particle (VLP) carrying on its surface at least one targeting molecule that binds to a cell of interest, the method comprising the step of contacting the polyomavirus or polyomavirus-derived VLP with (i) the targeting molecule, wherein the at least one targeting molecule is glycosylated with at least one glycosyl residue that is recognised by the polyomavirus or polyomavirus-derived VLP; or (ii) a first interaction molecule, wherein the first interaction molecule is glycosylated with at least one glycosyl residue that is recognised by the polyomavirus or polyomavirus-derived VLP; and the at least one targeting molecule, wherein the at least one targeting molecule is conjugated to a second interaction molecule capable of interacting with the first interaction molecule. The present invention further relates to a polyomavirus or polyomavirus-derived virus-like particle (VLP), wherein the virus or VLP carries on its surface at least one targeting molecule that binds to a cell of interest, as well as to a polyomavirus or polyomavirus-derived VLP obtained or obtainable by the method of the invention. Furthermore, the present invention relates to a composition comprising said polyomavirus or polyomavirus-derived VLP and to the use of the polyomavirus or polyomavirus-derived VLP of the invention or the composition of the invention for use as a medicament. The present invention further relates to a kit comprising the polyomavirus or polyomavirus-derived VLP or the composition of the invention.
• Ganglioside derivatives
  申请人：Fidia, S.p.A.

  公开号：US04713374A1

  公开（公告）日：1987-12-15

  New functional ganglioside derivatives comprising ester, amide and peracylated derivatives of gangliosides, preparation procedures therefor, pharmaceutical preparations containing the same, and the therapeutic use of the derivatives.

  新的功能性神经节苷脂衍生物，包括神经节苷脂的酯、酰胺和过酰化衍生物，以及其制备程序、含有它们的药物制剂和衍生物的治疗用途。